A phase I trial to evaluate the efficacy and safety of allogeneic bone marrow derived mesenchymal stem cell therapy in patients with diabetic retinopathy and diabetic optic neuropathy

Trial Profile

A phase I trial to evaluate the efficacy and safety of allogeneic bone marrow derived mesenchymal stem cell therapy in patients with diabetic retinopathy and diabetic optic neuropathy

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top